Halozyme's OCREVUS SC Gets European Approval for Multiple Sclerosis Treatment
Portfolio Pulse from Benzinga Newsdesk
Halozyme Therapeutics announced that Roche received European Commission marketing authorization for OCREVUS SC, co-formulated with Halozyme's ENHANZE, for the treatment of multiple sclerosis. The approval is based on Phase III trial data showing comparable efficacy and safety to the IV formulation.
June 25, 2024 | 7:11 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Halozyme Therapeutics' OCREVUS SC, co-formulated with ENHANZE, received European Commission approval for multiple sclerosis treatment. This approval is based on Phase III trial data showing comparable efficacy and safety to the IV formulation.
The European approval of OCREVUS SC, co-formulated with Halozyme's ENHANZE, is a significant milestone for Halozyme. It validates the efficacy and safety of their technology and opens up a new market in the EU, likely boosting investor confidence and stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100